STAA Gains FDA Nod to Expand EVO ICL Age Indication to 60 Years

Key Takeaways STAAR Surgical won FDA approval to expand EVO ICL use to patients aged 21 to 60 years.STAA shares rose 8.4% after data showed strong safety and rising U.S. adoption trends.STAAR Surgical sees growth as LASIK declines and 24M U.S. adults may qualify for EVO ICL.STAAR Surgical (STAA) recently announced that the FDA has approved an expanded age indication for its EVO/EVO+ Visian Implantable Collamer Lenses (EVO ICL), extending eligibility in the United States to patients aged 21 to 60 years. Prev ...